Efficacy and safety of an extended-release niacin (Niaspan): A long- term study

American Journal of Cardiology

Volumn 82, Issue 12 A, 1998, Pages 74U-81U

  Capuzzi, David M ^a,b   Guyton, John R ^a   Morgan, John M ^a   Goldberg, Anne C ^a   Kreisberg, Robert A ^a   Brusco, O A ^a   Brody, Jerome ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Cardiovasc Dis Prevention Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; SUSTAINED RELEASE PREPARATION;

EID: 0032542302     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00731-0     Document Type: Conference Paper

References (20)

1. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on cholesterol in man. Arch Biochem Biophys 1955;54:558-559.
2. Charman RC, Matthews LB, Braeuler C. Nicotinic acid in the treatment of hypercholesterolemia. Angiology 1972;23:29-35.
3. DiPalma JR, Thayer WS. Use of niacin as a drug. Annu Rev Nutr 1991;11: 169-187.
4. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. NIH Publication No. 93-3095.
5. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381.
6. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Priness RJ, Friedewald W. Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 1986;8:1245-1255.
7. Morgan JM, Capuzzi DM, Guyton JR, Centor RM, Goldberg R, Robbins DC, Dipette D, Jenkins S, Marcovina S. Treatment effect of Niaspan, a controlled-released niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther 1996;1:195-202.
8. Carlson LA, Rosenhamer G. Reduction in mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-414.
9. Blankenhorn DH, Azen SP, Crawford DW, Nessim SA, Sanmarco ME, Selzer RH, Shircore AM, Wickham EC. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation 1991;83:438-447.
10. Malloy MJ, Kane JP. Aggressive medical therapy for the prevention and treatment of coronary artery disease. Dis Mon 1998;44:5-40.
11. Knopp RH, Ginsberg J, Algers JJ, Hoff C, Ogilvia JT, Warnick GR, Burrows E, Retzlaff B, Poole M. Contrasting effects of unmodified and time-release forms of niacin in lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985:34:642-650.
12. McKenney JM, Proctor JD, Harris S, Chimcili VM. A comparison of the efficacy and toxic effects of sustained vs immediate-release niacin in hypercholesterolemia patients. JAMA 1994;271:672-677.
13. Knopp RH. Niacin and hepatic failure. (Letter.) Ann Intern Med 1991;111: 769.
14. Mullin GE, Greenson JK, Mitchell MC. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med 1989;111:253-255.
15. Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O'Connor CM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998;82:737-74.
16. Genest JJ Jr, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991;67: 1185-1189.
17. Shepherd J, Packard C, Patsch J. Effects of nicotinic acid therapy on plasma high-density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 1979;63:858-867.
18. Lavie CJ, Mailander L, Milani RV. Marked benefit with sustained-release niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol 1992;69: 1083-1085.
19. Guyton JR, Capuzzi DM. Treatment of hyperlipidemia with combined niacin/statin regimens. Am J Cardiol 1998;82:82U-84U.
20. Loscalzo J. Lipoprotein(a): a unique risk factor for atherothrombotic disease. Arteriosclerosis 1990;10:672-679.